Skip to search formSkip to main contentSkip to account menu

BMS 907351

Known as: BMS-907351, BMS907351 
National Institutes of Health

Related topics

Related topics

3 relations
XL184

Broader (2)

cabozantinibcabozantinib s-malate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
An adaptive randomized discontinuation trial of XL184 (BMS-907351) in patients (pts) with advanced solid tumors.
TPS188 Background: XL184 is an oral, potent inhibitor of MET, VEGFR2, and RET with promising activity in phase I and II trials… 
2010
2010
408 Phase 2 study of XL184 (BMS-907351) in a cohort of patients (pts) with hepatocellular carcinoma (HCC)
2010
2010
Abstract 377: Inhibition of c-Met and VEGFR by XL184 reduces tumor invasiveness and metastasis and prolongs survival of RIP-Tag2 transgenic mice
Recent studies have shown that inhibition of VEGF signaling can promote tumor invasiveness and metastasis in some preclinical… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)